Practical Journal of Organ Transplantation(Electronic Version) ›› 2021, Vol. 9 ›› Issue (6): 463-466.DOI: 10.3969/j.issn.2095-5332.2021.06.008

Previous Articles     Next Articles

Clinical research of serum CRP in predicting recurrence of  hepatocellular carcinoma after liver transplantation

Li Wei1,Ren Xiuyun2,Shi Bin3,You Bo3,Pan Yipeng1   

  1. 1.Department of Transplantation,The Second Affiliated Hospital of HainanMedical University,Haikou 570000,Hainan,China ;

    2. Department of Ultrasound,Hainan Hospital of PLA General Hospital,Sanya 572000,Hainan,China ;

    3.Department of Transplantation,the Third Medical Center of PLA General Hospital,Beijing 100039,China

  • Online:2021-11-20 Published:2022-03-11

血清 CRP 检测在预测肝癌肝移植术后复发的临床研究

李威 1,任秀昀 2,史斌 3,游波 3,潘宜鹏 1   

  1. 1. 海南医学院第二附属医院器官移植科,海南 海口 570000 ;

    2. 解放军总医院海南医院超声科,海南 三亚 572000 ;

    3. 解放军总医院第三医学中心移植科,北京 100039)

Abstract:

Objective To investigate the significance of serum C-reactive protein(CRP)in predicting liver cancer recurrence after liver transplantation. Methods Retrospective analysis was performed on the clinical data of 65 patients undergoing liver transplantation for liver cancer from March 2013 to March 2019. The patientswere divided into positive group(CRP ≥ 8 mg/L)and the negative group(CRP < 8 mg/L). The collected data were statistically analyzed. Results Of the 65 patients,45(75.0%)met milan criteria and 32(49.2%)had a history of pre-transplant treatment. In the multivariate analysis,serum CRP ≥ 8 mg/L was an independent risk factors for HCC recurrence. The 2-year recurrence rates of the two groups were 74.3% and 14.8%,respectively(HR = 10.36,95% CI = 3.89 ~ 27.61,P = 0.000). There was also a statistically significant difference in overall survival between the positive group and the negative group(P = 0.000). Conclusion Preoperative test of CRP can predict the recurrence of liver cancer after liver transplantation and predict the prognosis of patients.

Key words:

C-reactive protein, Hepatocellular carcinoma, Liver transplantation, Recurrence

摘要:

目的 探讨血清 C 反应蛋白(C-reactive protein,CRP)预测肝移植术后肝癌复发的价值。方法 回顾性分析本中心 2013 年 3 月至 2019 年 3 月 65 例肝癌行肝移植术患者的临床资料,阳性组(CRP ≥ 8 mg/L),阴性组(CRP < 8 mg/L),对搜集的相关数据进行统计分析。结果 65 例患者中,45 例(75.0%)符合米兰标准,32 例(49.2%)移植前治疗史。阳性组 30 例(46.2%),在多变量分析中血清 CRP ≥ 8 mg/L 是肝癌复发的独立危险因素,两组 2 年复发率分别为 74.3% 和 14.8%(HR = 10.36,95% CI = 3.89 ~ 27.61;P = 0.000)。阳性组与阴性组的患者总体生存期亦具有明显统计学差异(P = 0.000)。结论 术前 CRP 检测可预测肝移植术后肝癌复发并提示患者预后。

关键词:

C 反应蛋白 , 肝癌 , 肝移植 , 复发